NeuroMetrix,
Inc. (Nasdaq: NURO), a medical device company focused on the
treatment and management of chronic pain, peripheral neuropathies, and
related neurological disorders, today announced that it will exhibit at
the annual fall Medtrade trade show and conference on October 8-10 in
Orlando. Medtrade is the largest home medical equipment (HME) tradeshow
and conference in the US. It brings together hundreds of HME
manufacturers and thousands of durable medical equipment (DME) providers
with home health care professionals for an annual product review and
sourcing opportunity. The SENSUS™ Pain Management System will be
presented in the “Product Spotlight” at the Medtrade New Product
Pavilion.
SENSUS is a convenient and wearable non-invasive electrical nerve
stimulator that offers patients a fast-acting, non-narcotic option for
relief from chronic pain. The device is lightweight and can be worn
during the day while remaining active, or at night while sleeping. It is
specifically designed for people with diabetes that suffer from chronic
pain. The most common cause of such pain is painful diabetic neuropathy
(PDN), which affects up to 5 million people in the U.S. alone.
NeuroMetrix intends to use the conference as an opportunity to meet DME
providers and distributors interested in adding SENSUS to their product
offerings. The company’s representatives at Medtrade will include Shai
N. Gozani M.D., Ph.D., NeuroMetrix President and Chief Executive
Officer. The conference will be held at the Orange County Convention
Center in Orlando, Florida and the NeuroMetrix exhibition will be at
location #1263 on the tradeshow floor. Further information on Medtrade
is available at: http://www.medtrade.com/show/about-the-show.shtml
About NeuroMetrix
NeuroMetrix is a medical device company that develops and markets home
use and point-of-care devices for the treatment and management of
chronic pain, peripheral neuropathies, and associated neurological
disorders. The Company is presently focused on diabetic neuropathies,
which affect over 50% of people with diabetes. If left untreated,
diabetic neuropathies trigger foot ulcers that may require amputation
and cause disabling chronic pain. The annual cost of diabetic
neuropathies has been estimated at $14 billion in the United States. The
company markets the SENSUS™ Pain Management System for treating chronic
pain, focusing on physicians managing patients with painful diabetic
neuropathy. The company also markets the DPNCheck® device,
which is a rapid, accurate, and quantitative point-of-care test for
diabetic neuropathy. This product is used to detect diabetic neuropathy
at an early stage and to guide treatment. For more information, please
visit http://www.neurometrix.com.
Copyright Business Wire 2013